Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

An Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1B

In this page

Clinical Trial

NCT02065011 Terminated
An Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1B

An Open-Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1B.

Phase 3
Interventional

Disease

Disease type

Hereditary retinal disease

Retinitis Pigmentosa

Usher Syndrome

Orphan drug recognition

NA

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

27/11/2015

Closing date

20/03/2035

Inclusion criteria :

More

Exclusion criteria :

More

Funding

industry

Members involved

Main investigators

Pr José-Alain Sahel

France

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Others investigators

Pr Isabelle Audo

Representative

France

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

ERN EYE member investigating site

HCP : Principal investigators